China SXT Pharmaceuticals (China SXT Pharmaceuticals) Net Income From Continuing Operations : $-14.14 Mil (TTM As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is China SXT Pharmaceuticals Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. China SXT Pharmaceuticals's net income from continuing operations for the six months ended in Sep. 2023 was $-9.70 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Sep. 2023 was $-14.14 Mil.

China SXT Pharmaceuticals Net Income From Continuing Operations Historical Data

The historical data trend for China SXT Pharmaceuticals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China SXT Pharmaceuticals Net Income From Continuing Operations Chart

China SXT Pharmaceuticals Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Net Income From Continuing Operations

Get a 7-Day Free Trial

1.54

-10.29

-2.75

-5.74

-5.94

China SXT Pharmaceuticals Semi-Annual Data
	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Net Income From Continuing Operations	Get a 7-Day Free Trial									-3.09	-2.64	-1.50	-4.44	-9.70

China SXT Pharmaceuticals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-14.14 Mil.

China SXT Pharmaceuticals (China SXT Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China SXT Pharmaceuticals Inc (NAS:SXTC) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

2RY0:Germany

Address

No. 178 Taidong Road North, Jiangsu, Taizhou, CHN, 225300

Website

http://www.sxtchina.com

China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, Advanced TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates a majority of its revenue from the People's Republic of China.